Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study

被引：0
|
作者：
Ching-Liang Ho
Tsu-Yi Chao
Chia-Lun Chang
Hsuan-Yu Lin
机构：
[1] Tri-Service General Hospital,Division of Hematology and Oncology
[2] National Defense Medical Center,Division of Hematology and Oncology
[3] Taipei Tzu Chi Hospital,Division of Hematology and Oncology
[4] Buddhist Tzu Chi Medical Foundation,Division of Hematology and Oncology
[5] Taipei Medical University-Shuang Ho Hospital,Division of Hematology and Oncology, Department of Internal Medicine
[6] Ministry of Health and Welfare,undefined
[7] Taipei Municipal Wanfang Hospital,undefined
[8] Changhua Christian Hospital,undefined
来源：
BioDrugs | 2024年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：287 / 299
页数：12
相关论文
共 50 条
  • [41] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Safety and preliminary efficacy of different doses of fecal microbiota capsule transplantation combined with anti-PD-1 inhibitor for patients with advanced malignant solid tumors
    Zhu, Wenyu
    Chu, Yunqian
    Xue, Ya
    Hu, Muni
    Dai, Hanjue
    Xian, Qingying
    Jiang, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
    Oaknin, A.
    Ellard, S. L.
    Leath, C., III
    Moreno, V.
    Kristeleit, R.
    Guo, W.
    Lu, S.
    Jenkins, D.
    McEachern, K.
    Jen, K. Yu
    Dunlap, S.
    Im, E.
    Gilbert, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 334 - 334
  • [44] First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors
    Gomez-Roca, Carlos
    Champiat, Stephane
    Cassier, Philippe
    Jegou, David
    Primard, Marie
    Petain, Aurelie
    Gueguen-Dorbes, Genevieve
    Fabre, Claire
    Melero, Ignacio
    Marabelle, Aurelien
    CANCER RESEARCH, 2024, 84 (07)
  • [45] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
  • [46] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
  • [47] Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
    Desai, Jayesh
    Deva, Sanjeev
    Lee, Jong Seok
    Lin, Chia-Chi
    Yen, Chia-Jui
    Chao, Yee
    Keam, Bhumsuk
    Jameson, Michael
    Hou, Ming-Mo
    Kang, Yoon-Koo
    Markman, Ben
    Lu, Chang-Hsien
    Rau, Kun-Ming
    Lee, Kyung-Hun
    Horvath, Lisa
    Friedlander, Michael
    Hill, Andrew
    Sandhu, Shahneen
    Barlow, Paula
    Wu, Chi-Yuan
    Zhang, Yun
    Liang, Liang
    Wu, John
    Paton, Virginia
    Millward, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [48] Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.
    Kelly, Karen
    Patel, Manish R.
    Infante, Jeffrey R.
    Iannotti, Nicholas
    Nikolinakos, Petros
    Leach, Joseph
    Wang, Ding
    Chandler, Jason Claud
    Jerusalem, Guy Heinrich Maria
    Gurtler, Jayne S.
    Arkenau, Hendrik-Tobias
    Speit, Isabell
    von Heydebreck, Anja
    Chin, Kevin M.
    Heery, Christopher Ryan
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [50] Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC).
    Bai, Xueli
    Chen, Yiwen
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16131 - E16131
12345